( 您好!臺灣時間:2021/03/03 23:13
字體大小: 字級放大   字級縮小   預設字形  


研究生(外文):Yu-Shiuan Yuan
論文名稱(外文):The molecular mechanism of Visfatin affecting the sensitivity of kidney cancer cells to target drugs
指導教授(外文):Chen Cheng-Nan
外文關鍵詞:renal epithelial cancer cellVisfatinSREBP-1AstaxanthinSunitinib
  • 被引用被引用:0
  • 點閱點閱:21
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
中文摘要 I
Abstract II
致謝 III
目錄 V
附圖目錄 VIII
圖目錄 IX
第一章緒論 1
第一節 研究背景 1
第二節 研究目的 4
第二章文獻探討 5
第一節 腎臟細胞癌 5
第二節 腎細胞癌的藥物治療 6
第三節 脂肪激素 9
第四節 肥胖對於癌症影響 16
第五節 Sterol regulatory element binding proteins (SREBPs) 脂質轉錄因子 17
第六節 MAPK pathway (mitogen-activated protein kinases pathway) 21
第七節 PI3K/Akt pathway 23
第八節 蝦紅素(Astaxanthin) 25
第三章材料與方法 27
第一節 實驗材料與試劑 27
第二節 實驗器材與儀器 31
第三節 試劑配置 33
第四節 實驗方法 36
第四章實驗結果 46
一、Sunitinib對於腎臟上皮癌細胞株786-O的毒殺能力 46
二、Visfatin誘導下腎臟上皮癌細胞786-O對於抗癌藥Sunitinib的抗藥性影響 46
三、Visfatin 誘導下腎臟上皮癌細胞786-O的抗藥性情形下對於PI3K/Akt、ERK 路徑的細胞存活率的影響 47
四、Visfatin 誘導下腎臟上皮癌細胞786-O的抗藥性情形下對於ERK和PI3K/Akt 磷酸化的蛋白質表現 48
五、Visfatin 誘導下腎臟上皮癌細胞786-O脂質轉錄因子SREBP-1的蛋白質表現 49
六、 抑制脂質轉錄因子SREBP-1對於腎臟上皮癌細胞786-O的影響 49
七、在Visfatin的刺激下抑制SREBP-1對於腎臟上皮癌細胞786-O及Sunitinib藥物治療的影響 50
八、 蝦紅素(Astaxanthin)對於腎臟上皮癌細胞786-O細胞存活率的影響 51
九、蝦紅素 (Astaxanthin) 顯著提升低濃度Sunitinib對於細胞毒殺能力及降低Visfatin對於藥物抗藥性 52
十、 抑制SREBP-1與蝦紅素(Astaxanthin)作用對於ERK/Akt pathway 蛋白質表現 53
第五章討論 54
參考文獻 57
結果附圖 64
1. Tahbaz R, Schmid M, Merseburger AS. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Current Opinion in Urology. 2018;28(1):62-79.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer. 2013;49(6):1374-1403.
3. Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Current Opinion in Oncology. 2008;20(3):300-306.
4. Lipworth L, Tarone RE, Lund L, McLaughlin JK. Epidemiologic characteristics and risk factors for renal cell cancer. Clinical Epidemiology. 2009;1:33-43.
5. Organization WH. Obesity: preventing and managing the global epidemic: report of a WHO consultation on obesity, Geneva, 3-5 June 1997. World Health Organization Technical Report Series. 1998.
6. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Annals of the New York Academy of Sciences. 2012;1271:37-43.
7. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.
8. Dalamaga M, Karmaniolas K, Chamberland J, Nikolaidou A, Lekka A, Dionyssiou-Asteriou A, et al. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. Metabolism. 2013;62(12):1830-1839.
9. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocrine Reviews. 2012;33(4):547-594.
10. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-430.
11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7-30.
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: A Cancer Journal for Clinicians. 2009;59(4):225-249.
13. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, et al. Molecular diagnosis and therapy of kidney cancer. Annual Review of Medicine. 2010;61:329-343.
14. Marencak J, Ondrusova M, Ondrus D. [Recent Overview of Kidney Cancer Diagnostics and Treatment]. Klin Onkol.30(3):175-181.
15. Linehan W. DeVita, Hellmand, and Rosenberg's cancer: principles and practice of oncology. Cancer of The Kidney. 2011:1161-1182.
16. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89(3):604-614.
17. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. Journal of Urology. 2010;183(4):1309-1315.
18. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017;15(6):804-834.
19. Sidana A, Srinivasan R. Therapeutic Strategies for Hereditary Kidney Cancer. Current Oncology Reports. 2016;18(8):50.
20. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275(33):25733-25741.
21. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Advances in Chronic Kidney Disease. 2014;21(1):81-90.
22. de Velasco G, Hamieh L, Mickey S, Choueiri TK. Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urologic Oncology. 2015;33(12):538-545.
23. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. The New England Journal of Medicine. 2003;349(5):427-434.
24. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics. 2008;7(10):3129-3140.
25. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. 2007;356(2):125-134.
26. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology. 2009;27(20):3312-3318.
27. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research. 2003;9(1):327-337.
28. Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. The Journal of Biological Chemistry. 2007;282(28):20534-20543.
29. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
30. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456.
31. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2548-2556.
32. Parham P. The immune system: Garland Science; 2014.
33. 陳明德. 脂肪激素. 台灣醫學. 2003;7(6):935-938.
34. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144(9):3765-3773.
35. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806.
36. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes/Metabolism Research and Reviews. 2011;27(6):515-527.
37. Sonoli SS, Shivprasad S, Prasad CV, Patil AB, Desai PB, Somannavar MS. Visfatin--a review. European Review for Medical and Pharmacological Sciences. 2011;15(1):9-14.
38. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, Woo CW, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. The Journal of Biological Chemistry. 2008;283(50):34833-34843.
39. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Letters. 2003;544(1-3):74-78.
40. Dalamaga M, Christodoulatos GS. Visfatin, obesity, and cancer. Adipocytokines, Energy Balance, and Cancer: Springer; 2017. p. 109-136.
41. Zhang LQ, Heruth DP, Ye SQ. Nicotinamide Phosphoribosyltransferase in Human Diseases. Journal of Bioanalysis & Biomedicine. 2011;3:13-25.
42. Koumaki V, Dalamaga M. NAMPT (nicotinamide phosphoribosyltransferase). Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2012.
43. Duarte-Pereira S, Silva SS, Azevedo L, Castro L, Amorim A, Silva RM. NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples. Scientific Reports. 2014;4:6311.
44. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Letters. 2006;580(17):4105-4113.
45. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends in Endocrinology and Metabolism. 2009;20(3):130-138.
46. Bae YH, Bae MK, Kim SR, Lee JH, Wee HJ, Bae SK. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochemical and Biophysical Research Communications. 2009;379(2):206-211.
47. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovascular Research. 2008;78(2):356-365.
48. Trichopoulos D, Adami HO, Ekbom A, Hsieh CC, Lagiou P. Early life events and conditions and breast cancer risk: from epidemiology to etiology. International Journal of Cancer. 2008;122(3):481-485.
49. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology. 2007;178(3):1748-1758.
50. Moschen AR, Gerner RR, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Current Pharmaceutical Design. 2010;16(17):1913-1920.
51. Romacho T, Sanchez-Ferrer CF, Peiro C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators of Inflammation. 2013;2013:946427.
52. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochimica et Biophysica Acta. 2008;1783(5):886-895.
53. Liu F-H, Song J-Y, Shang X-R, Meng X-R, Ma J, Wang H-J. The gene-gene interaction of INSIG-SCAP-SREBP pathway on the risk of obesity in Chinese children. BioMed Research International. 2014;2014.
54. Hua X, Sakai J, Brown MS, Goldstein JL. Regulated cleavage of sterol regulatory element binding proteins requires sequences on both sides of the endoplasmic reticulum membrane. The Journal of Biological Chemistry. 1996;271(17):10379-10384.
55. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331-340.
56. Eberle D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86(11):839-848.
57. Sato R. Sterol metabolism and SREBP activation. Archives of Biochemistry and Biophysics. 2010;501(2):177-181.
58. 58. Jeon T-I, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends in Endocrinology & Metabolism. 2012;23(2):65-72.
59. 59. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metabolism. 2011;14(1):21-32.
60. 闵雪洁, 赵丽, 赵小平. SREBP 在肿瘤中的研究进展. 上海交通大学学报 (医学版). 2016;36(08):1256.
61. Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Research. 2013;73(9):2850-2862.
62. Zhu Z, Zhao X, Zhao L, Yang H, Liu L, Li J, et al. p54 nrb/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A. Oncogene. 2016;35(11):1399.
63. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer & Metabolism. 2013;1(1):3.
64. Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89(6):867-882.
65. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291.
66. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and Molecular Biology Reviews. 2011;75(1):50-83.
67. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Molecular and Cellular Biochemistry. 2003;253(1-2):269-285.
68. Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, et al. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science. 1990;249(4964):64-67.
69. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911-1912.
70. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends in Biochemical Sciences. 2001;26(11):657-664.
71. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
72. Guo H, German P, Bai S, Barnes S, Guo W, Qi X, et al. The PI3K/AKT pathway and renal cell carcinoma. Journal of Genetics and Genomics. 2015;42(7):343-353.
73. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery. 2014;13(2):140-156.
74. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer. 2009;9(8):550-562.
75. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics. 1999;21(1):99-102.
76. Hemmings BA, Restuccia DF. Pi3k-pkb/akt pathway. Cold Spring Harbor Perspectives in Biology. 2012;4(9):a011189.
77. Visioli F, Artaria C. Astaxanthin in cardiovascular health and disease: mechanisms of action, therapeutic merits, and knowledge gaps. Food Funct. 2017;8(1):39-63.
78. Yuan JP, Peng J, Yin K, Wang JH. Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Molecular Nutrition & Food Research. 2011;55(1):150-165.
79. Lorenz RT, Cysewski GR. Commercial potential for Haematococcus microalgae as a natural source of astaxanthin. Trends in Biotechnology. 2000;18(4):160-167.
80. Kishimoto Y, Yoshida H, Kondo K. Potential Anti-Atherosclerotic Properties of Astaxanthin. Marine Drugs. 2016;14(2).
81. Aoi W, Naito Y, Takanami Y, Ishii T, Kawai Y, Akagiri S, et al. Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of oxidative CPT I modification. Biochem Biophys Res Commun. 2008;366(4):892-897.
82. Terao J. Antioxidant activity of beta-carotene-related carotenoids in solution. Lipids. 1989;24(7):659-661.
83. Goto S, Kogure K, Abe K, Kimata Y, Kitahama K, Yamashita E, et al. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochimica et Biophysica Acta. 2001;1512(2):251-258.
84. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49(4):744-747.
85. Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetology & Metabolic Syndrome. 2010;2:21.
86. Sampath D, Zabka TS, Misner DL, O'Brien T, Dragovich PS. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacology & Therapeutics. 2015;151:16-31.
電子全文 電子全文(網際網路公開日期:20241123)
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔